{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:57:25Z","timestamp":1777993045734,"version":"3.51.4"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,1,6]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an often deadly complication of IPF. No focussed international guidelines for the management of AE-IPF exist. The aim of this international survey was to assess the global variability in prevention, diagnostic and treatment strategies for AE-IPF.<\/jats:p><jats:p>Pulmonologists with ILD expertise were invited to participate in a survey designed by an international expert panel.<\/jats:p><jats:p>509 pulmonologists from 66 countries responded. Significant geographical variability in approaches to manage AE-IPF was found. Common preventive measures included antifibrotic drugs and vaccination. Diagnostic differences were most pronounced regarding use of Krebs von den Lungen-6 and viral testing, while high-resolution computed tomography, brain natriuretic peptide and D-dimer are generally applied. High-dose steroids are widely administered (94%); the use of other immunosuppressant and treatment strategies is highly variable. Very few (4%) responders never use immunosuppression. Antifibrotic treatments are initiated during AE-IPF by 67%. Invasive ventilation or extracorporeal membrane oxygenation are mainly used as a bridge to transplantation. Most physicians educate patients comprehensively on the severity of AE-IPF (82%) and consider palliative care (64%).<\/jats:p><jats:p>Approaches to the prevention, diagnosis and treatment of AE-IPF vary worldwide. Global trials and guidelines to improve the prognosis of AE-IPF are needed.<\/jats:p>","DOI":"10.1183\/13993003.01760-2019","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T16:25:19Z","timestamp":1581697519000},"page":"1901760","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":90,"title":["Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation"],"prefix":"10.1183","volume":"55","author":[{"given":"Michael","family":"Kreuter","sequence":"first","affiliation":[]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[]},{"given":"Simon L.F.","family":"Walsh","sequence":"additional","affiliation":[]},{"given":"Johannes","family":"Krisam","sequence":"additional","affiliation":[]},{"given":"Harold R.","family":"Collard","sequence":"additional","affiliation":[]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[]},{"given":"Sergey","family":"Avdeev","sequence":"additional","affiliation":[]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-0775","authenticated-orcid":false,"given":"Gregory","family":"Calligaro","sequence":"additional","affiliation":[]},{"given":"Tamera","family":"Corte","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Flaherty","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Funke-Chambour","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Molina Molina","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8348-8651","authenticated-orcid":false,"given":"Antonio","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[]},{"given":"Julie","family":"Morisset","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Silvia","family":"Quadrelli","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-4783","authenticated-orcid":false,"given":"Moises","family":"Selman","sequence":"additional","affiliation":[]},{"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[]},{"given":"Vanesa","family":"Vicens-Zygmunt","sequence":"additional","affiliation":[]},{"given":"Julia","family":"W\u00e4lscher","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-3497","authenticated-orcid":false,"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[]},{"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"2024102101201763000_55.4.1901760.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2024102101201763000_55.4.1901760.2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12931-019-1037-7","article-title":"Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"2024102101201763000_55.4.1901760.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2024102101201763000_55.4.1901760.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01339-2016"},{"key":"2024102101201763000_55.4.1901760.5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101201763000_55.4.1901760.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024102101201763000_55.4.1901760.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2017"},{"key":"2024102101201763000_55.4.1901760.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200709-1365OC"},{"key":"2024102101201763000_55.4.1901760.9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12890-018-0643-3","article-title":"Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights","volume":"18","author":"Faverio","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024102101201763000_55.4.1901760.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203740"},{"key":"2024102101201763000_55.4.1901760.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.04.009"},{"key":"2024102101201763000_55.4.1901760.12","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.21037\/jtd.2018.08.60","article-title":"Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Nikaido","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024102101201763000_55.4.1901760.13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12931-017-0511-3","article-title":"Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis","volume":"18","author":"Molyneaux","year":"2017","journal-title":"Respir Res"},{"key":"2024102101201763000_55.4.1901760.14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12890-017-0437-z","article-title":"Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study","volume":"17","author":"Kawamura","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024102101201763000_55.4.1901760.15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7150\/ijms.4972","article-title":"Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Ding","year":"2013","journal-title":"Int J Med Sci"},{"key":"2024102101201763000_55.4.1901760.16","doi-asserted-by":"publisher","DOI":"10.1513\/pats.2306030"},{"key":"2024102101201763000_55.4.1901760.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201010-1752OC"},{"key":"2024102101201763000_55.4.1901760.18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.rmed.2018.02.003","article-title":"Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases","volume":"136","author":"Saraya","year":"2018","journal-title":"Respir Med"},{"key":"2024102101201763000_55.4.1901760.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2024102101201763000_55.4.1901760.20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12890-015-0146-4","article-title":"Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach","volume":"15","author":"Papiris","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2024102101201763000_55.4.1901760.21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2359"},{"key":"2024102101201763000_55.4.1901760.22","first-page":"385","article-title":"Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a single center experience and literature review","volume":"33","author":"Novelli","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024102101201763000_55.4.1901760.23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4327"},{"key":"2024102101201763000_55.4.1901760.24","doi-asserted-by":"crossref","first-page":"e0127771","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PLoS One"},{"key":"2024102101201763000_55.4.1901760.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061409"},{"key":"2024102101201763000_55.4.1901760.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102101201763000_55.4.1901760.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00539-2019"},{"key":"2024102101201763000_55.4.1901760.28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/resp.12909","article-title":"Bronchoscopy assessment of acute respiratory failure in interstitial lung disease","volume":"22","author":"Arcadu","year":"2017","journal-title":"Respirology"},{"key":"2024102101201763000_55.4.1901760.29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.rmed.2018.09.011","article-title":"Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis","volume":"143","author":"Teramachi","year":"2018","journal-title":"Respir Med"},{"key":"2024102101201763000_55.4.1901760.30","first-page":"102","article-title":"Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis","volume":"11","author":"Rangappa","year":"2009","journal-title":"Crit Care Resusc"},{"key":"2024102101201763000_55.4.1901760.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2024102101201763000_55.4.1901760.32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.3222"},{"key":"2024102101201763000_55.4.1901760.33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/rccm.201508-1701OC","article-title":"Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure","volume":"193","author":"Trudzinski","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101201763000_55.4.1901760.34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12890-017-0426-2","article-title":"Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden","volume":"17","author":"Mooney","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024102101201763000_55.4.1901760.35","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001814"},{"key":"2024102101201763000_55.4.1901760.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00050911"},{"key":"2024102101201763000_55.4.1901760.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0138OC"},{"key":"2024102101201763000_55.4.1901760.38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102101201763000_55.4.1901760.39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102101201763000_55.4.1901760.40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-018-0866-0","article-title":"Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials","volume":"19","author":"Costabel","year":"2018","journal-title":"Respir Res"},{"issue":"Suppl. 59","key":"2024102101201763000_55.4.1901760.41","first-page":"OA4498","article-title":"Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib","volume":"46","author":"Cottin V","year":"2015","journal-title":"Eur Respir J"},{"key":"2024102101201763000_55.4.1901760.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0314OC"},{"key":"2024102101201763000_55.4.1901760.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01482-2016"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01760-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:28:58Z","timestamp":1740382138000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01760-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,3]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1183\/13993003.01760-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01760-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}